HR-positive HER2-negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

IRB# 21243
Neoadjuvant Abemaciclib and Niraparib (PANNTHR)

HER2-positive

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

Triple Negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

http://www.ohsu.edu/research/rda/so/knight.php
HR-positive
HER2-negative

IRB#22395
DARE: DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III

HER2-positive
No trials currently available

Triple Negative
No trials currently available

http://www.ohsu.edu/research/rda/scto/knight.php
**METASTATIC THERAPY**

- **1L**
  - **SERENA-4**: AZD9833 with palbociclib vs. anastrozole with palbociclib
  - **IRB#22730**

- **2L**
  - **OP-1250-001**: A Dose Escalation/Expansion study of OP-1250
  - **IRB#22225**
  - **IRB 22765 DESTINY Breast08**: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC
    - **IRB#22141**
    - **EA1183**: FDG-PET/CT

- **>2L**
  - **OP-1250-001**: A Dose Escalation/Expansion study of OP-1250
  - **IRB#22225**
  - **IRB 22765 DESTINY Breast08**: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC
    - **IRB#22141**
    - **EA1183**: FDG-PET/CT

- **HR-positive HER2-negative**
  - **Physician's Choice**

- **CHEMO**
  - **IRB 23524 TROPION Breast01**: DATO-DXd vs. Chemo
    - **IRB 23524 TROPION Breast01**: DATO-DXd vs. Chemo

- **CHEMO**
  - **IRB 23524 TROPION Breast01**: DATO-DXd vs. Chemo

- **In Development**
  - **Enrollment on Hold**

http://www.ohsu.edu/research/rda/so/knight.php
BREAST CANCER

METASTATIC THERAPY

HER2-positive

1L

IRB#21441
EA1183: FDG-PET/CT

2L

IRB#21441
EA1183: FDG-PET/CT

>2L

http://www.ohsu.edu/research/rda/so/knight.php

10 Aug 2022
METASTATIC THERAPY

1L

IRB#18504
AMTEC: Olaparib + Durvalumab

2L

IRB#18504
AMTEC: Olaparib + Durvalumab

IRB 22765 DESTINY-Breast08: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

>2L

IRB#18504
AMTEC: Olaparib + Durvalumab

IRB#22229: Early Phase 1 study of WEE1 inhibitor, ZN-c3

IRB 22765 DESTINY-Breast08: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

http://www.ohsu.edu/research/rda/so/knight.php
<table>
<thead>
<tr>
<th>Trial Number</th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB#15588</td>
<td>HEAVILY PRE-TREATED</td>
<td>HR+HER2-; HER2+; TNBC</td>
</tr>
<tr>
<td>(SMMART-PRIME)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#20679</td>
<td>HR+HER2-; HER2+; TNBC</td>
<td>PRE-SCREEN (MOLECULAR TARGET)</td>
</tr>
<tr>
<td>(SMMART-ACT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#19904</td>
<td>HEAVILY PRE-TREATED</td>
<td>PRE-SCREEN REQUIRED</td>
</tr>
<tr>
<td>NEO-RAY (Nuc Med)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#1992</td>
<td>PRE-SCREEN (MOLECULAR TARGET)</td>
<td></td>
</tr>
<tr>
<td>EAY131 (MATCH)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#18084</td>
<td>PRE-SCREEN (RARE MOLECULAR TARGET)</td>
<td></td>
</tr>
<tr>
<td>S1609 (DART)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#19489</td>
<td>TARGETING METASTATIC BREAST CANCER AND BREAST CANCER STEM CELLS WITH LUTATHERA</td>
<td></td>
</tr>
<tr>
<td>(Lutathera IIT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#16676</td>
<td>ADVANCED SOLID TUMOR WITH ONCOGENIC RET FUSION (EXPECTED TO CLOSE SOON)</td>
<td></td>
</tr>
<tr>
<td>BLU-667 (Phase 1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRB#18164</td>
<td>RET FUSION-POSITIVE</td>
<td></td>
</tr>
<tr>
<td>Loxo RET (Phase 1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

http://www.ohsu.edu/research/rda/so/knight.php
### TNBC:
- Previously treated (cytotoxic or targeted anticancer agents) in the metastatic setting.

- Patients must have progressed on at least two lines of approved therapy for their histological subtype.

- TNBC with no alternative effective standard therapy.

- TNBC relapsed/refractory to at least one line of systemic chemotherapy in the metastatic setting or intolerant of existing therapy(ies).

- Phase 1B: documented activating gene mutations in BRAF (BRAF V600 mutation or activating atypical non-V600 aberrations), KRAS, NRAS, or HRAS.

---

To inquire about Phase 1 trial open slots please contact Phase1@ohsu.edu.

http://www.ohsu.edu/research/rda/so/knight.php
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors. Principal Investigator: Richard Maziarz, MD

IRB# 23848
Carisma CT-0508

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid-Tumor Malignancies. Yazan Migdady, MD

IRB# 24318
Lyell 797-101

http://www.ohsu.edu/research/rda/so/knight.php